RedHill Biopharma Ltd. RDHL
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a GI/hepatology drug developer. Its lead program, Talicia (omeprazole, amoxicillin, rifabutin), is in Phase 2 for H. pylori infection.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Talicia | H. pylori infection (US marketed with Cumberland; ex-US out-licensed) | small molecule | Approved |
| RHB-102 (Bekinda, bimodal ondansetron) | Oncology support, gastritis/gastroenteritis, IBS-D, GLP-1/GIP-associated GI intolerance | small molecule | Phase 2 |
| Opaganib | Cancers (prostate, cholangiocarcinoma, CLL), viral ARDS, metabolic disorders, radiation protection | small molecule | Phase 2 |
| RHB-107 (upamostat) | COVID-19 and other viruses; oncology | small molecule | Phase 2 |
| RHB-104 | Crohn's disease / multiple sclerosis | small molecule | Phase 2 |
| RHB-204 | Nontuberculous mycobacterial (NTM) infections | small molecule | Phase 2 |
Recent results and decisions
- Jun 9, 2026n/a FDA granted rare pediatric disease designation to opaganib for neuroblastoma (designation only, not an approval; priority review voucher possible).
today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation to opaganib for treatment of neuroblastoma (NB).
Filing - Apr 30, 2026n/a New in vitro assays showed RHB-204 has MAP-killing efficacy comparable to RHB-104, at lower doses of two active ingredients; preclinical, not clinical.
The comparability results were achieved in both spot and phage assays of several different MAP strains.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.